


## Tyrosine kinase inhibitor

Cat. No.:	HY-10421		
CAS No.:	1021950-26-4		
Molecular Formula:	C <sub>31</sub> H <sub>31</sub> FN <sub>6</sub> O <sub>5</sub>		
Molecular Weight:	586.61		
Target:	c-Met/HGFR		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 46 mg/mL (78.42 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.7047 mL	8.5236 mL	17.0471 mL
	5 mM	0.3409 mL	1.7047 mL	3.4094 mL
	10 mM	0.1705 mL	0.8524 mL	1.7047 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.

#### In Vitro

Tyrosine kinases are important mediators of the signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism and apoptosis in response to external and internal stimuli<sup>[1]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. Inoue T, et al. Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. *World J Surg Oncol.* 2012 Aug 20;10(1):167.
- [2]. Bowen JM, et al. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. *Cancer Biol Ther.* 2012 Nov 1;13(13).
- [3]. Sun FK, et al. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. *Chin Med J (Engl).* 2012 Jun;125(12):2231-4.
- [4]. Thamm DH. Tyrosine kinase inhibitor special issue. *Vet Comp Oncol.* 2012 Sep;10(3):161-2. doi: 10.1111/j.1476-5829.2012.00339.x.
- [5]. Eriksson A, et al. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. *Blood Cancer J.* 2012 Aug 3;2:e81. doi: 10.1038/bcj.2012.28.
- [6]. Paul MK, et al. Tyrosine kinase - Role and significance in Cancer. *Int J Med Sci.* 2004;1(2):101-115.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA